Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis.

Published
August 25, 2023
Journal
Journal of integrative medicine
PICOID
72ffb9d6
DOI
Citations
1
Keywords
Meta-analysis, Pain, Placebo response, Primary dysmenorrhea, Sham acupuncture
Copyright
Copyright © 2023 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.
Patients/Population/Participants

female patients with primary dysmenorrhea

Intervention

sham acupuncture

Comparison

no intervention or other treatments

Outcome

pain intensity, retrospective symptom scale, health-related quality of life

Abstract

P
I
C
O

The placebo response of sham acupuncture in patients with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear. This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects. PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022. Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included. Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response. Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = -0.99; 95% confidence interval [CI], -1.31 to -0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = -0.20; 95% CI, -0.80 to -0.39. Average severity score: SMD = -0.35; 95% CI, -0.90 to -0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, -0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had < 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response. Strong placebo response and some relative factors were found in patients with primary dysmenorrhea. PROSPERO registration number: CRD42022304215. Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. J Integr Med. 2023; 21(5): 455-463.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.